Article
Hematology
John E. Wagner, Karen K. Ballen, Mei-Jie Zhang, Mariam Allbee-Johnson, Chatchada Karanes, Filippo Milano, Michael R. Verneris, Mary Eapen, Claudio G. Brunstein
Summary: This study evaluated outcomes in patients with hematological malignancy treated with myeloablative conditioning prior to haplo- or umbilical cord blood (UCB) HSCT. The study found that overall survival after haplo-HSCT with PTCy was comparable to that after UCB regardless of HLA match group, but UCB recipients had lower relapse rates and higher nonrelapse mortality.
Article
Oncology
Wenshuai Zheng, Yamei Wu, Lixun Guan, Longcan Cheng, Yalei Hu, Min Tan, Yuhui Yang, Hongmei Ning
Summary: This article describes the first successful cases of haploidentical hematopoietic stem cell transplantation from donors with mild alpha-thalassemia for patients with acute leukemia.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Asad Bashey, Xu Zhang, Lawrence E. Morris, H. K. Holland, Lizamarie Bachier-Rodriguez, Scott R. Solomon, Melhem Solh
Summary: The proportion of NFR AL/MDS patients undergoing HCT is low, but can be improved by integrating HCT/leukemia care and using haploidentical donors. Age and race are significant factors for failure to receive HCT.
Article
Oncology
Georg-Nikolaus Franke, Konstantin Dumann, Madlen Jentzsch, Astrid Monecke, Christine Doehring, Claudia Nehring-Vucinic, Sebastian Schwind, Dietger Niederwieser, Uwe Platzbecker, Mirjana Ziemer, Vladan Vucinic
Summary: This case demonstrates that alloHSCT can be a curative option for refractory SS patients. Achieving complete remission after tapering immunosuppressive therapy indicates the significant role of the GvL effect. The timing of alloHSCT and the intensity of conditioning should be further explored in current treatment algorithms for SS patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Andrea Pelosi, Francesca Besi, Nicola Tumino, Pietro Merli, Linda Quatrini, Giuseppina Li Pira, Mattia Algeri, Lorenzo Moretta, Paola Vacca
Summary: In the recent approach of HSC transplantation using G-CSF-mobilized graft from haploidentical donors, NK cells in the graft exhibit lower cytolytic activity compared to non-mobilized samples, while mobilized PMN-MDSCs have a unique transcriptional profile that distinguishes them from non-mobilized ones, indicating a strong inhibitory effect on donor NK cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Maite Alvarez, Antonio Pierini, Federico Simonetta, Jeanette Baker, Kristina Maas-Bauer, Toshihito Hirai, Robert S. Negrin
Summary: Allogeneic hematopoietic cell transplantation is an effective treatment option for hematological malignancies, but often results in severe toxicities. Less aggressive alternatives like NMAC and RIC have limitations including increased cancer relapse and limited persistence of donor chimerism. Strategies for accelerated and more durable donor engraftment are still needed.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Kimimori Kamijo, Yoshimitsu Shimomura, Akihito Shinohara, Shohei Mizuno, Minoru Kanaya, Yoshiaki Usui, Sung-Won Kim, Takahide Ara, Ishikazu Mizuno, Takuro Kuriyama, Hideyuki Nakazawa, Ken-ichi Matsuoka, Shigeru Kusumoto, Nobuo Maseki, Masaki Yamaguchi, Takashi Ashida, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Eisei Kondo
Summary: By comparing the effects of Flu/Bu2 and Flu/Bu4 on patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation, the study found that Flu/Bu4 was associated with higher nonrelapse mortality and lower 5-year overall survival compared to Flu/Bu2.
ANNALS OF HEMATOLOGY
(2023)
Article
Biophysics
Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Peter Remenyi, Gerard Socie, Gwendolyn van Gorkom, Helene Labussiere-Wallet, Xiao-Jun Huang, Marie Therese Rubio, Jenny Byrne, Charles Craddock, Laimonas Griskevicius, Fabio Ciceri, Mohamad Mohty
Summary: This study compared the outcomes of hematopoietic stem cell transplants in acute myeloid leukemia patients in first complete remission from different donor sources. The results showed that acute graft-versus-host disease (GVHD) was more common in all non-sibling donor groups. Chronic GVHD rates were also higher in certain unrelated donor groups. However, overall survival and leukemia-free survival did not differ significantly between donor types.
BONE MARROW TRANSPLANTATION
(2023)
Article
Engineering, Multidisciplinary
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
Summary: The development of Disease Risk Comorbidity Index (DRCI) based on Disease Risk Index (DRI) and Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) allows for effective risk stratification of patients receiving haploidentical hematopoietic stem cell transplantation. The DRCI accurately predicts disease-free survival, particularly in disease-specific subgroups such as acute leukemia patients. This index also shows predictive value for relapse, non-relapse mortality, overall survival, and can aid in identifying patients who will benefit most from the transplantation procedure.
Article
Biophysics
Yishan Ye, Mowang Wang, Florent Malard, Jimin Shi, Ying Lu, Guifang Ouyang, Jianping Lan, Yamin Tan, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Yibo Wu, Luxin Yang, Fei Gao, Mohamad Mohty, He Huang, Yi Luo
Summary: The study found that using NFD donors in haplo-HSCT produced similar outcomes to using FD donors. The type of donor did not significantly impact overall survival, progression-free survival, graft-versus-host disease incidence, or other outcomes.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Nobuaki Nakano, Atae Utsunomiya, Keitaro Matsuo, Noriaki Yoshida, Masao Seto, Kouichi Ohshima, Hiroshi Fujiwara, Shigeo Fuji, Yoshifusa Takatsuka, Ayumu Ito, Toshihiro Miyamoto, Youko Suehiro, Hirohisa Nakamae, Yasushi Sawayama, Mitsuhiro Yuasa, Yasuhiko Miyazaki, Shuichi Ota, Kazunori Imada, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Koji Kato
Summary: This study investigated the impact of chromosomal abnormalities on the survival of ATL patients after allo-HSCT, and found that certain structural breakpoints were independent risk factors for overall survival and ATL-related death.
Article
Medicine, General & Internal
Phillip C. Nguyen, Kate Manos, Chun Y. Fong, Anthony P. Schwarer, Ing S. Tiong, Andrew H. Wei, David Kliman, David J. Curtis
Summary: The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. A comparison of long-term outcomes in those aged 55-65 years in first remission showed that while 5-year overall survival and relapse-free survival were similar between transplant and chemotherapy only cohorts, transplantation was associated with increased non-relapse mortality.
INTERNAL MEDICINE JOURNAL
(2021)
Article
Biophysics
Dipenkumar Modi, Seongho Kim, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: Our study found no significant difference in outcomes between myeloablative conditioning (MAC) and reduced intensity conditioning (RIC) regimens in haploidentical peripheral blood stem cell transplant (haploPBSCT).
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermudez Rodriguez, Peter Remenyi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Summary: Comparing outcomes of adult patients with secondary acute myeloid leukemia (sAML) and de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide, no significant difference was observed in transplantation outcomes between the two groups.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Biophysics
Claire Michel, Marie Robin, Stephane Morisset, Didier Blaise, Johan Maertens, Patrice Chevalier, Cristina Castilla-Llorente, Edouard Forcade, Patrice Ceballos, Ibrahim Yakoug-Agha, Xavier Poire, Martin Carre, Jacques-Olivier Bay, Yves Beguin, Michael Loschi, Anne Huynh, Gaelle Guillerm, Sylvie Francois, Jean-Baptiste Mear, Remy Dulery, Felipe Suarez, Karin Bilger, Jerome Cornillon, Yves Chalandon, Natacha Maillard, Helene Labussiere-Wallet, Amandine Charbonnier, Pascal Turlure, Ana Berceanu, Sylvain Chantepie, Sebastien Maury, Ali Bazarbachi, Anne-Lise Menard, Stephanie Nguyen-Quoc, Marie-Therese Rubio, Maud D'Aveni
Summary: Allogeneic hematopoietic stem cell transplantation is the best option for treating higher-risk myelodysplastic syndrome. Patients with monosomal karyotype and/or complex karyotype abnormalities have lower survival rates after transplantation. This study compared outcomes in higher-risk MDS patients who received transplantation from HLA-matched sibling donors, HLA-matched unrelated donors, and HLA haploidentical donors. The results showed that the overall survival was better in the HLA-matched unrelated donor group.
BONE MARROW TRANSPLANTATION
(2023)